ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / IVVD
IPHA (46) CGEN (63) STRO (32) DTIL (30) ⌘ Pro Terminal →

Invivyd Inc. (IVVD) — RQD Stock Rating Cockpit

$0.58 +0.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.58

Invivyd Inc. (IVVD) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $171.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IVVD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IVVD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Invivyd Inc. (NASDAQ: IVVD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $0.58 (+0.05% 1D, market cap $171.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IVVD ranks #949 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IVVD compare to IPHA and CGEN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IVVD carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IPHA (Innate Pharma S.A. ADS) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $163.1M) and CGEN (Compugen Ltd.) posts a C grade (63/100 RQD, P/E 5.5x, ROIC 85.0%, cap $187.3M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IVVD?
▼

Per IVVD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001832038), Invivyd Inc. generated $53.4M in revenue (+110.5% YoY), -$52.5M in net income, and -$58.3M in free cash flow against $276.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.58 (-0.18%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510023
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk E
Cash (3)Whales (6)SEC (5)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-15.5% Base Target
$3 Bull$0 Base$0 Bear
📬 FREE IVVD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IVVD)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (23/100 Composite)
🔍 WHY IVVD SCORES 23/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+7/20 pts (30% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 36.2 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+6/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
31
Grade E$0.67-9% Next Q
Q2 (-2Q)
28
Grade E$0.61-3.3% Next Q
Q3 (-1Q)
26
Grade E$0.59-1.7% Next Q
Current
23
Grade E$0.58-11.1% Hist 90D α
Trajectory: E (31) → E (23)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IVVD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IVVD currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.78) and Max Pain ($0.61) forces dealer call-delta covering toward $3.22.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IVVD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IVVD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 23%NO 77%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
36.230 Oversold · 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
0.20>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $1$0.58H: $3
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 2 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 9 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 12 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on IVVD

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (15)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (25)

Altman-Z 0.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (27)

9/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like IVVD
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IVVD)

  • ✓Walkthrough of IVVD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IVVD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -60.54%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.60H $0.60L $0.58C $0.58VOL 5.38M
RES: $0.97SUP: $0.53SMA50: $0.78SMA200: $1.16
$1.78$1.44$1.10$0.76$0.42RES $0.97SUP $0.53$0.582026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IVVD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IVVD Butterfly Map → + Track IVVD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +110.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IVVD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IVVD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IVVD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IVVD)

Health Care Rank #949 of 1015 ⚔️ IPHA vs IVVD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IVVD vs. IPHA, CGEN, STRO, DTIL)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Invivyd Inc. (IVVD) ranks #949 by composite RQD confidence (23/100, grade E) and #591 by equity capitalization ($171.5M). Within this direct 5-issuer industry benchmark cohort, CGEN leads on earnings valuation at 5.5x trailing P/E, while CGEN leads on capital efficiency and profitability with 85.0% ROIC and 87.3% gross margin. CGEN currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with IVVD at 23/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IVVD ACTIVE
Invivyd Inc.
E 23/100 — — -35.0% +0.05% $171.5M Benchmark Subject
IPHA
Innate Pharma S.A. ADS
D 46/100 — — — -4.11% $163.1M /ipha-vs-ivvd →
CGEN
Compugen Ltd.
C 63/100 5.5x 87.3% 85.0% 0.00% $187.3M /cgen-vs-ivvd →
STRO
Sutro Biopharma Inc.
E 32/100 — — -35.0% +0.11% $150.9M /stro-vs-ivvd →
DTIL
Precision BioSciences Inc.
E 30/100 — — -35.0% -1.56% $194.9M /dtil-vs-ivvd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001832038 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Invivyd Inc. (IVVD) reported GAAP revenue of $53.4M (+110.5% vs. FY2024 revenue of $25.4M , and -91.0% cumulative change since FY2023) , GAAP net income of -$52.5M, operating cash flow of -$58.1M, and free cash flow of -$58.3M (+65.8% YoY). On the balance sheet, IVVD closed FY2025 with $276.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $53.4M -$52.5M -$58.1M -$58.3M $276.9M —
FY2024 (FY) 2024-12-31 $25.4M -$169.9M -$170.5M -$170.6M $129.5M —
FY2023 (FY) 2023-12-31 $595.7M -$198.6M -$173.2M -$173.2M — —

3. IVVD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IVVD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Invivyd Inc. (NASDAQ: IVVD) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $0.58 (+0.05% 1D, market cap $171.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IVVD ranks #949 in composite RQD confidence.

How does IVVD compare to IPHA and CGEN in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), IVVD carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IPHA (Innate Pharma S.A. ADS) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $163.1M) and CGEN (Compugen Ltd.) posts a C grade (63/100 RQD, P/E 5.5x, ROIC 85.0%, cap $187.3M). Among the 5-stock peer group, CGEN leads on earnings multiple (5.5x) while CGEN leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IVVD?

Per IVVD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001832038), Invivyd Inc. generated $53.4M in revenue (+110.5% YoY), -$52.5M in net income, and -$58.3M in free cash flow against $276.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IVVD trading relative to its 50-day, 200-day, and 52-week technical levels?

IVVD last traded at $0.58 (+0.05% on volume of 4,431,252 shares), positioning the stock -25.64% below its 50-day simple moving average ($0.78) and -50.00% below its 200-day simple moving average ($1.16). Across its 52-week range of $0.53 to $3.07, IVVD sits at the 2.0% percentile with a 14-day RSI of 36.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.65).

Direct Sub-Reports: IVVD RQD Cockpit IVVD 12M Forecast IVVD Earnings & Move IVVD Dividends & DRIP IVVD Insiders & 13F IVVD Whale Options IVVD Profit Sankey IVVD News & Why
ROARABLE RATING BRIEF • RQD 23/100 (E) ✓ SEC XBRL & RQD VERIFIED

IVVD — Invivyd Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Invivyd Inc. (IVVD) earns a live Roarable RQD composite score of 23/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.58 (+0.05% 1D, market capitalization $171.5M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Invivyd Inc. (IVVD) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry..2B. — describes its specific products, customers, or revenue model beyond the sector and industry classification.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Invivyd Inc. (IVVD) reported $53.4M in annual revenue (up from $25.4M in FY2024, +110.5% YoY) and -$52.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($595.7M revenue, -$198.6M net income) through FY2025, IVVD scaled operating cash flow to -$58.1M and free cash flow to -$58.3M, backed by $276.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 23/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $0.53 – $3.07 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— identifies upstream suppliers, downstream customers, or sector correlations beyond the Health Care sector and Biotechnology industry classification. Investors should watch regulatory progress on the VYD2311 program as the primary second-order driver, since source data ties the accelerated approval path to the Phase III readout.

  • Key Question #1: Can IVVD sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $53.4M and free cash flow of -$58.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is IVVD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

IVVD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Invivyd Inc. (IVVD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IVVD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IVVD Bull vs. Bear Conversation Board — What's Your Call at $0.58?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IVVD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IVVD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $0.71 (+22.4%)
📌 Pinned Debate

Cash rose to $226.7M in FY 2025 and the VYD2311 Phase III study reportedly met its safety goals while the company eyes FDA accelerated

The street is overcomplicating Invivyd Inc. (IVVD). Cash rose to $226.7M in FY 2025 and the VYD2311 Phase III study reportedly met its safety goals while the company eyes FDA accelerated approval.. With an RQD score of 23/100 (E) and Forensic Balance Sheet at 5/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $0.63.

VolSurface_Trader 🐂 BULL

@FadeTheHype Shorting a 6/20 institutional whale-flow stock at $0.58 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $0.46 (-20.7%)
Spot @ $0.58

ROIC of -35%, FCF yield of 0%, an Altman Z-Score of 0.2, and a Piotroski F-Score of 3/9 earn an RQD grade of E.

Careful chasing IVVD at $0.58. ROIC of -35%, FCF yield of 0%, an Altman Z-Score of 0.2, and a Piotroski F-Score of 3/9 earn an RQD grade of E.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $0.46 on multiple compression.

LIVE TAPE